European Society of Breast Cancer Specialists EJC online - The official journal of EUSOMA Improving Breast Cancer Care in Europa
ABOUT EUSOMAGUIDELINES & PUBLICATIONSBREAST UNITSNEWSEVENTSBECOME A MEMBER
   Search            Home       Site map       Links       FAQ       Contact Us            

 

 


Other Guidelines

The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?

Immunophenotype

All subtypes of LCIS are associated with oestrogen (ER) and progesterone receptor (PgR) expression (60-90% of cases positive) [17] [18]. The cells of LN also characteristically lack expression of E-cadherin, an epithelial cell membrane molecule involved in cell-cell adhesion [19] [20]. The cells of classic LCIS do not usually show amplification or expression of HER-2 and expression of TP53 is uncommon [17] [18] [21]. A number of authors have shown differences between classic LCIS and pleomorphic variant (PLCIS) [22], including a higher Ki67 (proliferation) index and more frequent expression of p53 and Her-2 in PLCIS, all of which may indicate a more aggressive profile. PLCIS can also express GCDFP-15 (gross cystic disease fluid protein-15), a marker of apocrine differentiation [22] [23].

 


Please use this address to send us any comments you want to make on the guidelines - we welcome your feedback: information@eusoma.org

 

     
 
Index
  Historical perspective
  Morphologic aspects
  Immunophenotype
  Risks associated with LCIS
  Molecular genetics
  Diagnosis and management
  Conflict of interest statement
  Acknowledgements
  References

 

 

| Webmaster | Privacy | Disclaimer | Credits |